An interventional study of Rehabilitation treatment with ATLAS2030 in Spinal Cord Injury (SCI), sponsored by MarsiBionics. Recruiting at 1 site in Spain. Open to participants aged 3 Years to 14 Years. Per ClinicalTrials.gov, last updated 2025-08-14.
Sponsored by MarsiBionics · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Spinal Cord Injuries with a site in Spain — 11 open to participants now, 13 under way, 1 of them phase 3. Spinal Cord Injuries · Spain.
Among the 59 studies in Spinal Cord Injuries with a site in Spain, this one is the 34th largest by planned enrollment of the 55 interventional ones that give a count, is one of 5 that started in 2025, is one of 34 with no phase, reaches primary completion later than 4 of the 12 other live ones, and was the 49th registered.
2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.
Browse Spinal Cord Injuries studies →11 of the 59 studies in Spinal Cord Injuries with a site in Spain are open now. Recruiting first, the newest first:
ABLE Human Motion S.L. · Sites in Spain
Ages 18–70
Technophage, SA · Sites in Spain
Ages 18–65
Institut Guttmann · Sites in Spain
Ages 18–99
University of Valencia · Sites in Spain
Ages 18–99
St George's, University of London · Sites in Spain, Austria, Belgium and 9 more countries
Ages 16+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.
This study: 3 Years to 14 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 14 · Phase 3 2 · Phase 4 2
First in 2005; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 24 across 1,639 interventional studies indexed under Spinal Cord Injuries.
Median enrollment 30 across the 55 interventional studies, 51 across the 4 observational. Of the 40 that completed or were terminated, 5 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 59 have an industry lead sponsor. The 10 most frequent:
MarsiBionics is the lead sponsor of 14 studies on the registry; 3 are open to participants now.
MarsiBionics has 4 studies filed under Spinal Cord Injuries — fewer than ten, so there is no comparison to draw.
4 of the studies in Spinal Cord Injuries with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06677229Technophage, SAPhase 1b/2a Clinical Trial to Determine the Safety, Tolerability and Efficacy of TZ-161 in Spinal Cord Injury | 2026-12 |
| NCT07745712ABLE Human Motion S.L.Clinical Investigation to Validate the Safety and Performance of the ABLE Kids Device in Pediatric Patients With Neurological Gait Disorders in a Clinical Setting | 2026-12-31 |
| NCT05142943University of ValenciaEffectiveness of Virtual Bodily Illusion Intervention in Upper Limb Motor Function in People With Incomplete Spinal Cord Injury. | 2026-12-31 |
| NCT07036107ABLE Human Motion S.L.A Trial on the Clinical and Socioeconomic Impact of Wearable Exoskeletons for Spinal Cord Injury Rehabilitation in the Spanish Healthcare System | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 59 studies in Spinal Cord Injuries with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to analyze the usability and safety of the robotic gait ATLAS 2030 in a cohort of pediatric patients with Spinal Cord Injury, with the aim of extending its indication for use to pediatric spinal cord injury
Spinal cord injury has a relatively low prevalence in the pediatric population, although its effects have significant physical and psychological consequences that greatly impact the quality of life of affected children. The ATLAS 2030 exoskeleton is a robotic gait device approved by the Spanish Agency of Medicines and Medical Devices for the rehabilitation of pediatric patients with cerebral palsy and spinal muscular atrophy. The principal aim is to analyze the safety and usability of the ATLAS 2030 exoskeleton during the implementation of a robotic gait training program with this device in a cohort of pediatric patients with spinal cord injury. the secondary aim is to analyze, in the same cohort of pediatric patients with spinal cord injury and through the implementation of the same therapeutic program, the efficacy of the ATLAS 2030 exoskeleton in improving fatigability, mood, health perception, and gait speed.
Ten sessions with the ATLAS 2030 exoskeleton will be conducted with pediatric patients with acute or chronic spinal cord injury. Additionally, two assessment sessions will be performed before and after the series of sessions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion criteria related to device characteristics:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The rehabilitation sessions will be carried out by a physiotherapist trained in rehabilitation with the ATLAS 2030 exoskeleton
Device: Rehabilitation treatment with ATLAS2030
10 sessions of Rehabilitation Treatment with ATLAS2030 with With an evaluation session before the first session and another one after 10 sessions.
Also known as: Robot Asissted Gait rehabilitation
Serious Adverse Events
occurrence of any serious adverse event to the participant
Time frame: From enrollment to the last assessment session at 8 weeks
Falls prevalence
Number of falling events occurred from the participant or caregiver
Time frame: From enrollment to the last assessment session at 8 weeks
Skin integrity
Occurrence of any injury of the skin in the areas of contact and produced by the use of the device
Time frame: From enrollment to the last assessment session at 8 weeks
Pain assessment
pain measured by the Visual Analogic Scale (VAS) by the participant, scored from 0 to 10, being 0 "no pain" and 10 "unbearable pain"
Time frame: From enrollment to the last assessment session at 8 weeks
Heart rate
measurement of heart rate
Time frame: from the beginning to the end of treatment at 6 weeks
Oxygen saturation
measurement of Oxygen saturation when medical prescription
Time frame: from the beginning to the end of treatment at 6 weeks
Blood pressure
measurement of blood pressure. Systolic and diastolic pressures will be assessed
Time frame: from the beginning to the end of treatment at 6 weeks
User and/or caregiver perception of the device
Questions that are scored from 0 to 5 on aspects related to comfort, weight, volume, etc
Time frame: From enrollment to the last assessment session at 8 weeks
Device usage data
Total walking time. Unit of Measure: Minutes.
Time frame: From enrollment to the last assessment session at 8 weeks
Number of steps
Number of steps with the device
Time frame: From enrollment to the last assessment session at 8 weeks
Usage modes
two different usage modes (active and automatic).
Time frame: From enrollment to the last assessment session at 8 weeks
Speed
speed achieved with the device (steps per minute)
Time frame: From enrollment to the last assessment session at 8 weeks
Range of motion
Passive Degree to which a joint can move (hip, knee, and ankle joints in both legs). From 0º to 180º.
Time frame: From enrollment to the last assessment session at 8 weeks
State of mind
It will be done with a Likert-type scale from 1 to 5 (1: very sad; 2: sad; 3: indifferent; 4: happy; 5: very happy). This scale will be administered before and after each therapeutic session.
Time frame: from the beginning to the end of treatment at 6 weeks
Health perception
EQ-5D scale assesses five dimensions of health: Mobility, Self-care, Usual activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has five levels of severity (No problems, Slight problems, Moderate problems, Severe problems, and Extreme problems).
Time frame: from enrollment to the last assessment session at 8 weeks
Health perception
Visual Analogue Scale (VAS) is a vertical scale where patients rate their current health on a scale from 0 to 100 (0 representing "the worst health you can imagine" and 100 representing "the best health you can imagine.
Time frame: from enrollment to the last assessment session at 8 weeks
10 Meter Walking Test (10 MWT) measured with ATLAS 2030
The 10 Meter Walking Test (10MWT) records the time taken by the participant to walk 10 meters with the device in motion intent mode.
Time frame: From enrollment to the last assessment session at 8 weeks
Effort perception
Borg Rating of Perceived Exertion (RPE), is a tool used to measure the intensity of physical activity based on how hard you feel your body is working. \- Modified Borg Scale (0-10): This version ranges from 0 to 10, where 0 means "nothing at all" and 10 means "very, very hard." It's often used in clinical settings to assess symptoms like breathlessness, chest pain, and muscle fatigue.
Time frame: from the beginning to the end of treatment at 6 weeks
Classification of Spinal Cord Injury
The International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) is a standardized tool for assessing and classifying spinal cord injuries Sensory function: Assessed in 28 dermatomes per side for light touch and pinprick sensations, scored as 0 (absent), 1 (impaired), or 2 (normal). Maximum score: 224 points (112 per modality). Motor function: Evaluated in 10 key muscle groups per side, using a 0-5 strength scale. Maximum score: 100 points. ASIA Impairment Scale: Classifies the severity of spinal cord injury into five categories: from A (complete) to E (normal).
Time frame: From enrollment to the last assessment session at 8 weeks
Disability
The Spinal Cord Independence Measure (SCIM) III. It is composed of 19 items that assess three main domains: * Self-care (6 items, scores range from 0-20) * Respiration and sphincter management (4 items, scores range from 0-40) * Mobility (9 items, scores range from 0-40) The total SCIM scores range from 0 to 100
Time frame: From enrollment to the last assessment session at 8 weeks
Walking ability
WISCI II (Walking Index for Spinal Cord Injury): Assess walking ability and level of assistance needed. Scoring: 0: Cannot walk. 20: Independent walking. Intermediate (1-19): Varies with assistive devices.
Time frame: From enrollment to the last assessment session at 8 weeks
Started Feb 2025 (actual). Primary completion is estimated for Feb 2026, 12 months after the start.
Of 49 industry-sponsored interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 12 months is below that.
Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
MarsiBionics